Creo Medical Group PLC
LSE:CREO

Watchlist Manager
Creo Medical Group PLC Logo
Creo Medical Group PLC
LSE:CREO
Watchlist
Price: 16.625 GBX 3.1% Market Closed
Market Cap: 68.5m GBX
Have any thoughts about
Creo Medical Group PLC?
Write Note

Gross Margin
Creo Medical Group PLC

49.5%
Current
42%
Average
47.2%
Industry

Gross Margin is the amount of money a company retains after incurring the direct costs associated with producing the goods it sells and the services it provides. The higher the gross margin, the more capital a company retains, which it can then use to pay other costs or satisfy debt obligations.

Gross Margin
49.5%
=
Gross Profit
15m
/
Revenue
30.3m

Gross Margin Across Competitors

Country UK
Market Cap 68.5m GBP
Gross Margin
50%
Country US
Market Cap 204.9B USD
Gross Margin
56%
Country US
Market Cap 195.2B USD
Gross Margin
67%
Country US
Market Cap 146.7B USD
Gross Margin
64%
Country US
Market Cap 132.6B USD
Gross Margin
69%
Country IE
Market Cap 110.6B USD
Gross Margin
66%
Country US
Market Cap 64.7B USD
Gross Margin
45%
Country DE
Market Cap 55.6B EUR
Gross Margin
38%
Country CN
Market Cap 319.2B CNY
Gross Margin
65%
Country US
Market Cap 41.6B USD
Gross Margin
79%
Country US
Market Cap 37.7B USD
Gross Margin
41%
No Stocks Found

Creo Medical Group PLC
Glance View

Market Cap
68.5m GBX
Industry
Health Care

Creo Medical Group Plc operates as a medical device company that focuses on surgical endoscopy. The company is headquartered in Chepstow, Monmouthshire/Sir Fynwy and currently employs 245 full-time employees. The company went IPO on 2016-12-09. The firm focuses on the field of surgical endoscopy. The company is focused on the development and commercialization of minimally invasive electrosurgical devices. The firm has developed CROMA, which delivers bipolar radiofrequency (RF) energy for precise localized cutting and focused microwave (MW) energy for controlled coagulation and ablation through a single accessory port. The company has three initial areas of clinical focus, which include in the Gastrointestinal (GI) tract, soft tissue ablation (including but not limited to the liver, pancreas, kidney), and lung interventions for the resection and/or ablation of precancerous and cancerous lesions. The firm has four technology families, which include Speedboat, MicroBlate, SlypSeal and SpydrBlade.

CREO Intrinsic Value
25.93 GBX
Undervaluation 36%
Intrinsic Value
Price

See Also

Discover More
What is Gross Margin?

Gross Margin is the amount of money a company retains after incurring the direct costs associated with producing the goods it sells and the services it provides. The higher the gross margin, the more capital a company retains, which it can then use to pay other costs or satisfy debt obligations.

Gross Margin
49.5%
=
Gross Profit
15m
/
Revenue
30.3m
What is the Gross Margin of Creo Medical Group PLC?

Based on Creo Medical Group PLC's most recent financial statements, the company has Gross Margin of 49.5%.